Home/Filings/4/0001209191-22-010710
4//SEC Filing

Olson Eric R 4

Accession 0001209191-22-010710

CIK 0001556263other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 4:08 PM ET

Size

10.3 KB

Accession

0001209191-22-010710

Insider Transaction Report

Form 4
Period: 2022-02-15
Olson Eric R
Chief Scientific Officer
Transactions
  • Award

    Restricted Stock Units

    2022-02-15+200,000200,000 total
    Common Stock (200,000 underlying)
  • Award

    Stock Option (right to buy)

    2022-02-15+100,000100,000 total
    Exercise: $1.59Exp: 2032-02-14Common Stock (100,000 underlying)
  • Award

    Restricted Stock Units

    2022-02-15+80,00080,000 total
    Common Stock (80,000 underlying)
Footnotes (4)
  • [F1]This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
  • [F2]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
  • [F3]These RSUs will vest in four equal annual installments commencing on March 31, 2023.
  • [F4]These RSUs will vest in full on March 31, 2025.

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother

Related Parties

1
  • filerCIK 0001678149

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:08 PM ET
Size
10.3 KB